NCT07469956 2026-03-13Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic CancerSun Yat-sen UniversityPhase 2 Not yet recruiting30 enrolled
NCT06577532 2025-05-21Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid TumorsRuijin HospitalPhase EARLY_PHASE1 Recruiting56 enrolled